ChronoScale Corporation Common Stock (NASDAQ:CHRN) Trading 6.1% Higher - Here's Why

Key Points

• CHRN shares rose 6.1% to $21.77 in mid-day trading, although trading volume was about 80% below its average.
• Analyst sentiment remains mixed: Northland Securities initiated coverage with an “outperform” rating and a $32 price target, while the broader consensus is “Hold” with a $19 target.
• The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue, alongside a negative net margin of 135.66%; institutional investors own 6.42% of the stock.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report)'s share price was up 6.1% during mid-day trading on Thursday . The stock traded as high as $21.83 and last traded at $21.77. Approximately 47,575 shares changed hands during trading, a decline of 80% from the average daily volume of 233,863 shares. The stock had previously closed at $20.51.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a report on Monday, August 24th. Northland Securities assumed coverage on shares of ChronoScale Corporation Common Stock in a research note on Friday, September 18th. They set an "outperform" rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $19.00.

ChronoScale Corporation Common Stock Price Performance

The firm has a market capitalization of $3.23 billion, a PE ratio of -4.12 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 0.51 and a current ratio of 0.51. The stock has a fifty day moving average price of $21.30 and a 200-day moving average price of $17.34.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.12) earnings per share for the quarter. ChronoScale Corporation Common Stock had a negative return on equity of 197.81% and a negative net margin of 135.66%.The company had revenue of $18.40 million for the quarter. Sell-side analysts forecast that ChronoScale Corporation Common Stock will post -0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc boosted its position in shares of ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,338 shares of the company's stock after acquiring an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent filing with the Securities & Exchange Commission. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.